Ignite Creation Date:
2025-12-24 @ 3:45 PM
Ignite Modification Date:
2026-02-01 @ 2:41 PM
Study NCT ID:
NCT05197192
Status:
RECRUITING
Last Update Posted:
2025-08-17
First Post:
2021-09-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
Sponsor:
German CLL Study Group
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Lymphocytic Leukemia | View |